作者: Santiago, Tharaga ; Mardale, Valentina ; Bayle, Nicolas ; Ghédira, Mouna ; Joudoux, Sandrine ; Boutou, Mina ; Hutin, Emilie ; Gault-Colas, Caroline ; Gracies, Jean-Michel

OBJECTIVEIn patients with Parkinson's disease, limited sit-to-stand, walk and turn contribute to decreased independence and quality of life. The 20-meter Ambulation Test (AT20) evaluates walking a total of 20 m, over a 10-m distance, back and forth between 2 chairs, starting and ending in a seated position. The aim of this study was to evaluate test-retest and inter-rater reliability of the AT20 in patients with Parkinson's disease.METHODSPatients with idiopathic Parkinson's disease performed the AT20 in 3 conditions: free speed, fast speed, and with large steps, twice 1 week apart. The total number of steps and the time to complete the task were recorded manually by 4 independent raters. The main outcome criteria were the test-retest and inter-rater intraclass correlation coefficients and coefficients of variation for speed, step length and cadence in the 3 conditions.RESULTSTwenty participants completed the 2 visits. Across all conditions, test-retest and inter-rater intraclass correlation coefficients for step length and speed were > 95%. Test-retest and inter-rater coefficients of variation were < 0.08.CONCLUSIONThe AT20 is a reliable ambulation test in Parkinson's disease, with excellent test-retest and inter-rater reliability for step length and speed in all 3 conditions: at free speed, fast speed, and with large steps. The AT20 might be useful to assess ambulation in parkinsonism in clinical practice.

2008-08-01·Vaccine3区 · 医学

Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17

3区 · 医学

Article

作者: Arnaldo Caruso ; Carlos A. Guzmán ; Maria Luisa Iaria ; Stefania Marsico ; Pablo D. Becker ; Simona Fiorentini ; Rosalinda Bruno

The major challenge for the development of a highly effective peptide-based vaccine is represented by the diversity of HIV-1 strains among human population. HIV-1 matrix protein p17 is a candidate antigen for therapeutic vaccines against AIDS. Here we show that antibodies elicited in animals by immunizing them with a synthetic peptide representative of the p17 functional epitope (AT20) derived from HIV-1 BH10 (clade B), neutralize the biological activity of p17 derived from divergent strains displaying critical mutations within AT20, by recognizing a highly conserved conformational epitope. This finding shows that AT20, as an immunogenic molecule, elicits broadly neutralizing anti-p17 antibodies.

100 项与 AT-20 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床1期	-	Medestea Internazionale Srl	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCERTAIN (ASH2023)	临床3期	急性髓性白血病	89	DEC-C (35 mg DEC/100 mg cedazuridine)	(鏇糧築顧窪艱蓋觸製餘) = 鬱簾衊顧壓艱壓膚餘窪鹽淵鑰願觸窪鬱鑰淵簾 (憲鹹築淵艱憲壓憲夢壓 ) 更多	-	2023-12-09
				IV-DEC at 20 mg/m2	壓製範繭積製餘構願餘(淵顧繭醖願膚鬱衊鑰壓) = 鹽餘選顧鬱鏇醖鏇蓋積觸鑰蓋醖簾夢襯構鹽鹽 (醖廠夢衊廠窪蓋廠蓋範 )